|
(ÁÖ)À¯ºñ¼Ò½Ã¾î½º |
¸ÞµðÄà Á¦Á¶¾÷ ÄÚ½º´Ú »óÀå±â¾÷, ±Û·Î¹ú ¸¶ÄÉÆà PM ¸ðÁý
¼¿ï °¼±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
11³â¡è |
ä¿ë½Ã |
10.05 |
|
|
ÁÖ½Äȸ»ç Å¥ºê¿¡ÀÌÄ¡¾Ë |
[PMS »ç¾÷ºÎ] CRA / CRA(oin-House) / MSA / ÀÓ»ó»ç¾÷PM
¼¿ï Á¾·Î±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
01.08 |
|
|
´õ ÈÞ¸Õ |
±¹³» À¯¸í»óÀåÁ¦¾à»ç Medical¸¶ÄÉÆÃPM (5~13³âÂ÷) ASAP
¼¿ï Á¾·Î±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
5³â¡è |
ä¿ë½Ã |
06.18 |
|
|
´õ ÈÞ¸Õ |
±¹³» À¯¸í»óÀåÁ¦¾à»ç R&BD Æ÷Áö¼Ç ASAP
°æ±â ¾È»ê½Ã ´Ü¿ø±¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
5³â¡è |
ä¿ë½Ã |
06.18 |
|
|
´õ ÈÞ¸Õ |
±¹³» À¯¸í»óÀåÁ¦¾à»ç PV ÆÀÀå±Þ Æ÷Áö¼Ç ASAP
¼¿ï Á¾·Î±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
3³â¡è |
ä¿ë½Ã |
05.19 |
|
|
ÄÚ¸®¾Æºê·¹ÀÎ ((ÁÖ)¿¡ÀÌÄ¡¾ËÇãºê) |
¼ö¼ú¼¾ÅÍ °£È£»ç ä¿ë
¼¿ï ÀüÁö¿ª | Çз¹«°ü |
°£È£»ç |
2³â¡è |
ä¿ë½Ã |
01.07 |
|
|
ÄÚ¸®¾Æºê·¹ÀÎ ((ÁÖ)¿¡ÀÌÄ¡¾ËÇãºê) |
Clinical Affairs Manager
¼¿ï ¸¶Æ÷±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
01.07 |
|
|
(ÁÖ)ÄھƼġ |
ÇصåÇåÅÍ,¸®¼Ã³
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
ÇìµåÇåÅÍ |
°æ·Â¹«°ü |
»ó½Ãä¿ë |
08.05 |
|
|
(ÁÖ)ÄھƼġ |
market access
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
1³â¡è |
ä¿ë½Ã |
07.01 |
|
|
(ÁÖ)ÄھƼġ |
Product manager
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
4³â¡è |
ä¿ë½Ã |
07.01 |
|
|
(ÁÖ)ÄھƼġ |
Product manager
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
4³â¡è |
ä¿ë½Ã |
07.01 |
|
|
±¹³» L±×·ì Á¦¾à»ç |
°Ç°±â´É½ÄÇ° MR
¼¿ï Á¾·Î±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°Ç°º¸Á¶½ÄÇ°/ÈÀåÇ°¿µ¾÷ |
5³â¡è |
ä¿ë½Ã |
06.04 |
|
|
±¹³» »óÀ§Á¦¾à»ç |
±¹³» »óÀ§Á¦¾à»ç °³¹ß°£ºÎ »ç¿ø ¸ðÁý
¼¿ï ¼´ë¹®±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
10³â¡è |
ä¿ë½Ã |
05.31 |
|